Cerivastatin contraindications

List of contraindications
Liver disease Gemfibrozil treatment Pregnancy and lactation Hypersensitivity
 * Possible fetal harm

Liver disease
Active liver disease or unexplained persistent elevations of serum transaminases. Return to top

Gemfibrozil treatment
Concurrent treatment with gemfibrozil due to a risk for rhabdomyolysis. Return to top

Pregnancy and lactation
Atherosclerosis is a chronic process, and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. Return to top

Possible fetal harm
Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, HMG-CoA reductase inhibitors are contraindicated during pregnancy and in nursing mothers. Cerivastatin sodium should be administered to women of child-bearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking this drug, cerivastatin sodium should be discontinued and the patient should be apprised of the potential hazard to the fetus. Return to top

Hypersensitivity
Hypersensitivity to any component of this medication. Return to top